Skip to main content

Table 2 Adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

Toxicity

All grades

Grade 3 or higher

Hematologic

 Anemia

101

(97.1%)

18

(17.3%)

 Neutropenia

69

(66.3%)

44

(42.3%)

 Leukopenia

69

(66.3%)

25

(24.0%)

 Thrombocytopenia

73

(70.2%)

2

(1.9%)

Nonhematologic

 Febrile neutropenia

  

6

(5.8%)

 Anorexia

43

(41.3%)

1

(1.0%)

 Fatigue

89

(85.6%)

0

(0.0%)

 Stomatitis

32

(30.8%)

0

(0.0%)

 Diarrhea

63

(60.6%)

3

(2.9%)

 Constipation

50

(48.1%)

0

(0.0%)

 Nausea

71

(68.3%)

0

(0.0%)

 PN

93

(89.4%)

11

(10.6%)

 Edema in limbs

29

(27.9%)

0

(0.0%)

  1. PN peripheral sensory neuropathy